Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15:47 | Ex-FDA chief Peter Marks joins Eli Lilly's infectious disease unit | ||
13:37 | MapLight's $251m IPO sees schizophrenia drug developers on top | ||
13:37 | Affinia raises $40m for gene therapy development | ||
13:37 | Oragenics partners Receptor.AI for brain health candidate portfolio | ||
13:37 | CDC amends Covid-19, chickenpox immunisation schedule amid vaccine controversy | ||
13:37 | Lilly's Omvoh benefit continues for four years in UC | ||
Mo | Funds dry up for mRNA vaccines amid US political storm | ||
Mo | FDA backs generics onshoring push with ANDA priority scheme | ||
Mo | Rocket ditches blood disorder gene therapy in ongoing pipeline pivot | ||
Mo | Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy | ||
Mo | Jazz and Roche's Zepzelca-Tecentriq wins FDA ES-SCLC approval | ||
Mo | McMaster University and MIT discover new antibiotic for IBD | ||
Fr | FDA approves mifepristone generic as political abortion war rages on | ||
Fr | Takeda walks away from cell therapy in priority U-turn | ||
Fr | Amgen's Phase III data supports FDA label expansion of Repatha | ||
Do | FDA winds down operations amid government shutdown | ||
Do | FDA leaders are "acting political", says ex-agency chief counsel | ||
Do | Halozyme eyes microparticles in $900m Elektrofi acquisition | ||
Do | AbbVie breaks ground on $70m US biologics site amid Trump pressure | ||
01.10. | US Government shuts down over funding impasse | ||
01.10. | Pfizer shakes hands with White House on drug discounts under MFN programme | ||
01.10. | Klotho to acquire Turn Biotechnologies' assets | ||
01.10. | Star Therapeutics gains $125m Series D funds to develop pipeline | ||
01.10. | Disruption due for long-held assumptions in biopharma, says BIA chair | ||
30.09. | Genmab to acquire Merus shares for $8bn |